Physician profile
Deepinder S Burn
NPI 1639182124
$10,296.45
in general payments reported to CMS, 2019-2025
46 companies · $996 in 2025
The $996 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $1,790 · 2021: $1,714 · 2022: $1,944 · 2023: $1,472 · 2024: $1,023 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.13 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,266.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,122.81 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $1,029.64 | 2019-2025 | Breztri, Fasenra, Farxiga |
| Amgen INC. | $862.02 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $823.37 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $690.60 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $657.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $651.70 | 2019-2024 | Belsomra, Steglatro, Segluromet |
| Vanda Pharmaceuticals INC. | $384.59 | 2019-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $318.61 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Sunovion Pharmaceuticals INC. | $249.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.65 | 2019-2024 | Trintellix |
| Allergan, INC. | $194.82 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $163.49 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepinder Burn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.